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Human pituitary tumour-transforming gene 1 (hPTTG1)
is an oncogenic transcription factor that is overexpressed
in many tumour types, especially tumours with metastatic
abilities. However, how hPTTG1 overexpression drives
metastasis is not yet clear. As a transcription factor,
hPTTG1 may promote metastasis by activating target
genes that are involved in the metastatic process. Here, we
showed that Rho guanine nucleotide exchange factor-H1
(GEF-H1) was transcriptionally activated by hPTTG1,
thereby promoting breast cancer metastasis. Luciferase
reporter analyses and chromatin immunoprecipitation
(ChIP) assays showed that hPTTG1 directly bound and
activated the GEF-H1 gene promoter. In this study, RNA
interference-mediated knockdown of hPTTG1 in highly
metastatic breast tumour cells decreased GEF-H1 expres-
sion and RhoA activation, thereby reducing cell motility
and invasion, and interfering with cytoskeletal remodelling
in vitro, and impairing the tumour metastasis in vivo. The
restoration of GEF-H1 expression in hPTTG1-knockdown
cells rescued the hPTTG1-knockdown effects on cytoske-
letal changes in vitro and tumour metastasis in vivo.
Conversely, ectopic expression of hPTTG1 in non-meta-
static breast tumour cells induced cytoskeletal rearrange-
ments, and allowed these cells to metastasise in a mouse
model by orthotopic implantation. In human tumour
samples, hPTTG1 expression was also correlated to
GEF-H1 expression in aggressive breast carcinoma.
Altogether, these ﬁndings deﬁnitively establish a role for
hPTTG1 in activating the GEF-H1/RhoA pathway as a
newly identiﬁed mechanism in breast cancer metastasis.
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Introduction
Metastasis is the major cause of death in cancer patients
(Gupta and Massague, 2006), but how these tumour
cells become metastatic is not wholly understood. The
invasion-metastasis cascade is a multistep process,
involving the invasion of tumour cells into adjacent
sites, intravasation into the systemic circulation, survival
of tumour cells during the stress of circulation,
extravasation into distant tissues, and establishment of
micrometastases and outgrowth of secondary tumours
(Chambers et al., 2002; Fidler, 2003).
Human pituitary tumour-transforming gene 1
(hPTTG1), which encodes the human securin protein
(Pei and Melmed, 1997; Zou et al., 1999) is a multi-
functional gene. In cell-cycle regulation, hPTTG1
controls sister chromatid separation during mitosis
(Funabiki et al., 1996; Hornig et al., 2002). Moreover,
hPTTG1 protein can interact with a variety of proteins
that are important for the regulation of cellular
circuitry; these proteins include PBF, PP2A, Ku70 and
p53 (Chien and Pei, 2000; Romero et al., 2001; Bernal
et al., 2002; Gil-Bernabe et al., 2006). For example,
hPTTG1 regulates DNA-damage repair mechanisms
through its interaction with Ku70 protein and inhibits
the Ku70-dependent repair process (Romero et al.,
2001). hPTTG1 has also been characterised as a
transcription factor that regulates the expression of
genes involved in a variety of cellular processes (Wang
and Melmed, 2000; Vlotides et al., 2007; Tong and
Eigler, 2009). hPTTG1 transcriptionally activates onco-
genes such as c-myc and ﬁbroblast growth factor (FGF)-
2 (Chien and Pei, 2000; Pei, 2001), but detailed
mechanisms of how hPTTG1 promotes metastasis
through the induction of these target genes are still
unclear.
hPTTG1 behaves as an oncogene whose overexpres-
sion transforms ﬁbroblasts in vitro and enhances
tumourigenesis in vivo (Zhang et al., 1999; Zou et al.,
1999). In several clinical studies, hPTTG1 was found to
be overexpressed in most invasive solid tumours and
blastic leukaemias (Dominguez et al., 1998; Heaney
et al., 2000; Ogbagabriel et al., 2005; Ito et al., 2008).
It is also recognised as one of the ‘signature molecules’ for
metastasis (Ramaswamy et al., 2003). hPTTG1 over-
expression is considered a potential marker that is
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www.nature.com/oncrelevant to the malignancy of breast cancer (Solbach
et al., 2004; Ogbagabriel et al., 2005). However, how
overexpressed hPTTG1 promotes breast cancer metas-
tasis remains unknown.
We hypothesised that hPTTG1 exerts its metastasis-
promoting functions by acting as a transcriptional
activator for genes involved in the metastatic process.
Here, we found that hPTTG1 directly regulated the
transcription of guanine nucleotide exchange factor-H1
(GEF-H1), which is an oncoprotein that speciﬁcally
activates RhoA (Ren et al., 1998), a well-known member
of the Rho family of GTPases. Activated RhoA
mediates multiple signals that are involved in cytoske-
leton organisation, cell motility, cell invasion and cell
proliferation (Hall, 1998; Schmitz et al., 2000; Ridley,
2001; Mizuarai et al., 2006). All of these events
contribute to tumour metastasis (del Peso et al., 1997;
Jaffe and Hall, 2005). Although the role of RhoA in
cancer development and metastasis has been thoroughly
investigated in recent years (Valastyan et al., 2009; Chan
et al., 2010), the upstream regulation of GEF-mediated
RhoA activation is still unclear. In this study, we show
that hPTTG1 is a transcription factor that triggers the
GEF-H1/RhoA pathway to accelerate breast cancer
invasion and metastasis. In human invasive breast
carcinoma, we also found that hPTTG1 is overexpressed
and is correlated to GEF-H1 expression.
Results
hPTTG1 level affects GEF-H1 expression in breast
cancer cell lines
To search for putative genes regulated by hPTTG1, we
compared the expression proﬁle of hPTTG1-null
HCT116 cells with those cells overexpressing hPTTG1
(Supplementary Figure S1a). There were 49 genes that
were upregulated by at least threefold in hPTTG1-null
HCT116 and hPTTG1-overexpressing cells when com-
pared with hPTTG1-null HCT116 cells. Among these
upregulated genes, seven genes are involved in tumour-
igenesis (Supplementary Table S1). To investigate the
role of hPTTG1 in tumour metastasis, we focused on
GEF-H1, whose activity is regulated by microtubule
dynamics in cytoskeleton organisation (Krendel et al.,
2002) and is associated with tumourigenesis (Mizuarai
et al., 2006). Hence, we validated the messenger RNA
(mRNA) and protein expression levels of GEF-H1 in
hPTTG1-overexpressed cells by real-time PCR and
immunoblot analysis (Supplementary Figures S1a
and b).
Increased expression of hPTTG1 is a risk factor of
breast cancer (Ogbagabriel et al., 2005). To investigate
the association of hPTTG1 and GEF-H1 in breast
cancer, we examined the expression status of hPTTG1
and GEF-H1 in eight breast cancer cell lines: normal
human mammary epithelial cells (H184B5F5/M10), ﬁve
non-metastatic cancer cell lines (BT-483, Au565, T-47D,
ZR75-1 and MCF-7) and two metastatic cancer cell lines
(MDA-MB-231 and MDA-MB-435). Higher levels of
hPTTG1 protein were observed in most breast cancer
cell lines when compared with H184B5F5/M10 normal
mammary epithelial cells (Figure 1a; Supplementary
Figure S2a). Quantiﬁcation of western blots indicated
that hPTTG1 protein was expressed more highly
(ranging from 1.3-fold to 3.4-fold) in breast cancer cell
lines than normal mammary epithelial cells (Supple-
mentary Figure S2a). Similarly, most breast cancer cell
lines expressed higher levels of both GEF-H1 mRNA
(ranged from 2- to 4-fold) and protein (ranging from 7-
to 20-fold), especially in metastatic cancer cell lines,
when compared with normal epithelial mammary cells
(Figure 1a; Supplementary Figure S2b). These results
indicate that the expression level of hPTTG1 affects the
expression of GEF-H1 in breast cancer cell lines,
especially in metastatic breast cancer cells.
hPTTG1 functions as a transcription factor to
transactivate the GEF-H1 gene in breast cancer cells
To investigate whether hPTTG1 regulates GEF-H1 tran-
scription, we cloned the regulatory sequence of the GEF-H1
gene (from 1600bp upstream to 98bp downstream of the
transcription start site) into the pGL3 luciferase vector for
luciferase reporter assays. We found that GEF-H1
transcriptional activity was enhanced by hPTTG1 over-
expression (Figure 1b). This result suggests that hPTTG1
regulates GEF-H1 by transcriptional activation.
hPTTG1 is a functional transcription factor, and the
sequence of a hPTTG1-binding element has been
identiﬁed as TTATCT (Pei, 2001). Based on this sequence,
we found that the promoter region of GEF-H1 contained
three putative (TTaACT, TTcTCT and TTATgT)
hPTTG1-binding elements (Figure 1b). To conﬁrm
whether hPTTG1 activated GEF-H1 transcription
through any of these three putative binding elements
directly, we generated two truncation mutants with 50
deletions of the GEF-H1 promoter (Figure 1c). Our
results show that the transcriptional activity of fragment
B, which contains putative hPTTG1-binding elements 2
and 3, was not induced by hPTTG1 (Figure 1c), whereas
the transcriptional activity of fragment C, which contains
only putative hPTTG1-binding element 3, was induced by
hPTTG1 slightly, suggesting that hPTTG1 may regulate
GEF-H1 transcription by binding on putative binding
element 1 or 3. Next, we used electrophoretic mobility
shift assay (EMSA) to assess whether hPTTG1 binds to
the GEF-H1 promoter. Addition of the  1160/ 1140
probe to recombinant hPTTG1 protein formed speciﬁc
binding complex that was competed by homologous
competitors (Supplementary Figure S3, lanes 2–3). How-
ever, addition of the  1005/ 986 and  275/ 257 probes
to recombinant hPTTG1 protein did not form binding
complex (Supplementary Figure S3, lanes 6–7). These
results suggest that the promoter region between  1160
and  1140bp may be critical for hPTTG1 binding, and
this region contains putative hPTTG1-binding element 1.
To verify the possibility that putative hPTTG1-
binding element 1 is critical for GEF-H1 transcription,
we mutated putative hPTTG1-binding element 1 and
analysed its reporter activities. Mutation of putative
hPTTG1-binding element 1 signiﬁcantly attenuated the
hPTTG1-induced activation of the GEF-H1 promoter
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transcription through binding element 1. Further, a
chromatin immunoprecipitation (ChIP) assay was per-
formed in vivo to determine whether hPTTG1 interacts
with the endogenous GEF-H1 promoter in MDA-MB-
231 cells. The ChIP assay revealed that the promoter
region containing the element 1 was speciﬁcally co-
immunoprecipitated by anti-hPTTG1 antibody, whereas
hPTTG1 knockdown signiﬁcantly attenuated this effect
(Figure 1e). We found that hPTTG1 also had slight
Figure 1 hPTTG1 is a transcriptional activator of GEF-H1. (a) Immunoblot analysis of hPTTG1 and GEF-H1 expression in all eight
cell lines. b-Actin was used as a loading control (top). The transcript level of GEF-H1 was analysed by real-time PCR. GAPDH was
used as the loading control (bottom). (b) The GEF-H1 regulatory sequence contains three putative hPTTG1-binding elements (binding
element 1: nucleotides  1158 to  1153; binding element 2: nucleotides  998 to  993; binding element 3: nucleotides  269 to  264)
(top). hPTTG1 activates the GEF-H1 promoter in MCF-7 cells. The GEF-H1 promoter was co-transfected with pcDNA3.1 vector
(Mock) or pcDNA3.1-hPTTG1 expression plasmid, and harvested for luciferase reporter assays (bottom). (c) A series of GEF-H1
promoter deletion mutants (fragments B and C, top) were used for luciferase reporter assays in MCF-7 cells (bottom). (d) A site-
speciﬁc mutation (TTAACT AAAACT) was introduced in the hPTTG1-binding element 1 on the GEF-H1 promoter and was co-
transfected with pcDNA3.1 vector (Mock) or pcDNA3.1-hPTTG1 expression plasmid in MCF-7 cells, and luciferase reporter assays
were performed. (e) ChIP assays were performed in MDA-MB-231 cells with GFP or hPTTG1 knockdown (hPTTG1 knockdown
efﬁciency is shown in Figure 2a). The ChIP-qPCR data are expressed as the fold increase over the control (IgG) on the promoter region
containing hPTTG1-binding elements 1, 2 and 3. (f) GEF-H1 mRNA expression was analysed by real-time PCR in MDA-MB-231
cells with GFP or PTTG1 knockdown, and in (g) MCF-7 cells transfected with pcDNA3.1 vector (Mock) or pcDNA3.1-hPTTG1.
Human GAPDH was used as the loading control. Results are presented as mean±s.e.m. (n¼3). ***Po0.0001; n.s., not signiﬁcant.
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signiﬁcantly affected by hPTTG1 knockdown
(Figure 1e). However, hPTTG1 had no binding capacity
to element 3. Although the above luciferase assay
showed that element 3 may function to regulate GEF-
H1 transcription, this result may have occurred because
fragment C contained other transcription factor sites.
These results suggest that hPTTG1 could directly bind
to the GEF-H1 promoter at element 1. Furthermore,
real-time PCR revealed that GEF-H1 mRNA expres-
sion was decreased in hPTTG1-knockdown MDA-MB-
231 cells (Figure 1f); conversely, GEF-H1 mRNA
expression was signiﬁcantly induced by hPTTG1 over-
expression in MCF-7 cells (Figure 1g). Altogether, these
results suggested that hPTTG1 functions as a transcrip-
tion factor to directly activate GEF-H1 transcription.
GEF-H1 mediates hPTTG1-enhanced breast cancer cell
migration and invasion
We next examined whether the hPTTG1 level is critical
for GEF-H1 protein expression. Metastatic MDA-MB-
231 and non-metastatic MCF-7 cells were utilised as
in vitro experimental models. MDA-MB-231 cells had
signiﬁcant metastatic potential in vitro and in vivo, and
expressed high levels of endogenous hPTTG1 and GEF-
H1 proteins (Figure 1a). Conversely, MCF-7 cells
expressed low levels of endogenous hPTTG1 and
GEF-H1 (Figure 1a). Knockdown of hPTTG1 expres-
sion by speciﬁc shRNAs in MDA-MB-231 cells resulted
in decreased GEF-H1 protein expression (Figure 2a).
In contrast, ectopic hPTTG1 expression in MCF-7 cells
profoundly increased GEF-H1 expression (Figure 2b).
As GEF-H1 is a speciﬁc guanine exchange factor for
RhoA-GTPase (Ren et al., 1998), we further conﬁrmed
whether the hPTTG1/GEF-H1 axis affects RhoA
activity. Indeed, the amount of activated RhoA-GTP
was reduced in hPTTG1-knockdown MDA-MB-231
cells, and was greatly increased by hPTTG1 over-
expression in MCF-7 cells (Figures 2c and d).
The speciﬁc role of RhoA in the acquisition of mobile
properties and invasive capacities in tumour cells has
been well-documented (Schmitz et al., 2000; Ridley,
2001). Thus, we hypothesised that hPTTG1/GEF-H1
signalling may be critical for cancer cell migration,
invasion and metastasis by activating RhoA. Indeed,
hPTTG1 knockdown reduced cell migration and inva-
sion in MDA-MB-231 cells (Figure 3a), whereas
hPTTG1 overexpression promoted cell migration and
invasion in MCF-7 cells (Figure 3b). hPTTG1 protein
transfection also rescued the ability of hPTTG1-knock-
down MDA-MB-231 cells to migrate and invade
(Supplementary Figure S4a). GEF-H1 knockdown or
overexpression phenocopied the effects of hPTTG1 on
migration and invasion (Figure 3c; Supplementary
Figure S4b), indicating that hPTTG1 may regulate
these processes by upregulating GEF-H1. To test this
idea, we restored GEF-H1 expression in hPTTG1-
knockdown MDA-MB-231 cells and found that restora-
tion of GEF-H1 expression rescued the defects of cell
migration and invasion caused by hPTTG1 knockdown
(Figure 3d). The effects of hPTTG1 and GEF-H1
knockdown on cell migration and invasion were due
to the biological activities of hPTTG1 and GEF-H1, as
hPTTG1 and GEF-H1 knockdown did not affect cell
proliferation or cell cycle progression (Supplementary
Figures S5a–c). Our results therefore suggest that
hPTTG1 enhances breast cancer cell migration and
invasion by inducing GEF-H1 signalling.
hPTTG1 regulates actin cytoskeleton rearrangements by
GEF-H1 signalling
As GEF-H1 activity is critical for RhoA activation,
GEF-H1 may regulate several RhoA-dependent biolo-
gical processes associated with the actin cytoskeleton,
such as cell morphology, polarity and motility (Hall,
1998; Sahai and Marshall, 2002). Modulation of RhoA
activity regulates cell retraction through the assembly of
F-actin stress ﬁbres and focal adhesions, two key
cytoskeletal events of migrating cells (Wittmann and
Waterman-Storer, 2001). To investigate whether
hPTTG1 regulates changes in the actin cytoskeleton to
enhance breast cancer cell motility, we monitored the
alterations of stress ﬁbres and focal adhesions by
staining for F-actin and paxillin, respectively. Paxillin
is a focal adhesion-associated protein and is required
for regulating cell spreading and motility (Schaller,
Figure 2 hPTTG1 regulates the expression of GEF-H1 and the activation of RhoA. (a) Immunoblot analysis of hPTTG1 and GEF-
H1 expression in control (not transfected with any DNA), GFP-knockdown or hPTTG1-knockdown MDA-MB-231 cells.
(b) Immunoblot analysis of hPTTG1 and GEF-H1 expression in MCF-7 cells transfected with pcDNA3.1 vector (Mock) or
pcDNA3.1-hPTTG1 expression plasmid. (c) Immunoblot analysis of active RhoA (RhoA-GTP) and total in control (not transfected
with any DNA), GFP-knockdown or hPTTG1-knockdown MDA-MB-231 cells. (d) Immnuoblot analysis of active RhoA (RhoA-
GTP) and total RhoA in MCF-7 cells transfected with pcDNA3.1 vector (Mock) or pcDNA3.1-hPTTG1 expression plasmid. The
relative intensity of protein was quantiﬁed by Quantity One software and normalised to b- actin and total RhoA.
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displayed a mesenchymal and spreading morphology
(Supplementary Figure S6; Figure 4A), with abundant
stress ﬁbres (Figure 4Ab) and punctate peripheral
paxillin staining (Figure 4Aa). However, hPTTG1-
knockdown MDA-MB-231 cells displayed epithelial-
like morphology, and spreading behaviour was attenu-
ated (Supplementary Figure S6; Figure 4A), with a
reduction in punctate paxillin staining (Figure 4Ad)
and stress ﬁbres (Figure 4Ae). In MCF-7 cells, both
hPTTG1 and GEF-H1 overexpression induced a
spreading morphology (Figure 4B), with an increase in
punctate paxillin staining (Figure 4Bd and g) and stress
ﬁbres (Figure 4Be and h) when compared with control
Mock-transfected MCF-7 cells (Figure 4Ba and b).
Furthermore, we found that restoration of GEF-H1
expression rescued the cell-spreading defect in hPTTG1-
kockdown MDA-MB-231 cells, with increased punc-
tate paxillin staining (Figure 4Ag) and stress ﬁbres
(Figure 4Ah). These results suggest that the hPTTG1/
Figure 3 hPTTG1 regulates cell migration and invasion through GEF-H1. (a) Migration and invasion assays in MDA-MB-231
cells with GFP or hPTTG1 knockdown (hPTTG1 knockdown efﬁciency is shown in Figure 2a). (b) Migration and invasion assays in
MCF-7 cells transfected with pcDNA3.1 vector (Mock) or pcDNA3.1-hPTTG1 expression plasmid (hPTTG1 overexpression efﬁciency
is shown in Figure 2b). (c) Migration and invasion assays and immunoblot analysis in MDA-MB-231 cells with GFP or GEF-H1
knockdown. (d) Migration and invasion assays and immunoblot analysis in MDA-MB-231 cells with GFP or hPTTG1 knockdown
or with hPTTG1 knockdown plus GEF-H1 overexpression. The relative intensity of protein was quantiﬁed by Quantity One software
and normalised to b- actin. Results are presented as mean±s.e.m. (n¼3). *Po0.05; **Po0.01; ***Po0.0001. Images shown in
Figure 3a–d show the migrating and invading cells in polycarbonate membrane ﬁlters. Magniﬁcation,  200. Scale bars, 200mm.
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in breast cancer cells.
To support our in vitro ﬁndings that hPTTG1
overexpression could enhance RhoA activation, we used
inhibitors of RhoA and its downstream molecule
ROCK (C3 transferase and 555550, respectively) to
treat hPTTG1-overexpressed MCF-7 cells and observe
the alteration of actin cytoskeleton dynamics. The
results show that the inhibition of RhoA signalling
abolished hPTTG1-induced cytoskeletal phenotypes in
hPTTG1-overexpressed MCF-7 cells (Figure 4C).
(ROCK is a downstream RhoA effector that facilitates
actin polymerisation and motility.) Both inhibitor-
treated cells displayed a reduction in punctate paxillin
staining (Figure 4Cd and g) and stress ﬁbres (Figure 4Ce
and h), when compared with hPTTG1-overexpressed
Figure 4 hPTTG1/GEF-H1 signalling regulates actin cytoskeleton rearrangements in breast cancer cells. (A) MDA-MB-231 cells with
GFP or hPTTG1 knockdown or with hPTTG1 knockdown plus GEF-H1 overexpression were immunostained with anti-paxillin antibody
(green) and phalloidin antibody (red) to observe focal adhesions and F-actin stress ﬁbres, respectively. Depletion of hPTTG1 expression in
MDA-MB-231 reduced the formation of focal adhesions (panel d), and F-actin stress ﬁbres (panel e) when compared with control shGFP-
knockdown MDA-MB-231 cells (panels a, b). Ectopic expression of GEF-H1 in hPTTG1-knockdown MDA-MB-231 cells increased
punctate paxillin staining (panel g) and F-actin stress ﬁbres (panel h). (B) Ectopic expression of hPTTG1 and GEF-H1 in MCF-7
cells induces the formation of focal adhesions (panels d, g), and F-actin stress ﬁbres (panels e, h) when compared with control MCF-7 cells
transfected with pcDNA3.1 vector (Mock; panels a, b). (C) hPTTG1-overexpressed MCF-7 cells were plated on poly-L-lysine-coated
coverslips for 48h and then treated with C3 transferase (RhoA inhibitor, 2mg/ml) or 555550 (ROCK inhibitor, 10mM) for 4 or 1.5h,
respectively. The inhibitor-treated cells were then ﬁxed and stained for DNA, focal adhesions (panels d, g) and F-actin (panels e, h). Both
inhibitors impaired the phenotypes induced by hPTTG1. The vehicle-treated cells were shown in panels a–c. Scale bars, 20mm. Merged
images of paxillin and F-actin were shown in panels c, f and i of A–C. DAPI (blue) was used to visualize the nuclei.
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Our results indicate that the hPTTG1/GEF-H1 axis
regulates actin dynamics by activating RhoA signalling,
thus enhancing the motility and invasive potential of
breast cancer cells.
The hPTTG1/GEF-H1 axis is critical for breast cancer
metastasis in a mouse model
To further evaluate the role of the hPTTG1/GEF-H1 axis
in mestastasis, we orthotopically injected the control
shGFP-knockdown and hPTTG1-knockdown MDA-
MB-231 cells into the fourth mammary fat pads of severe
combined immunodeﬁciency (SCID) mice and monitored
tumour growths weekly. The results show that hPTTG1
knockdown did not affect primary tumour growth within
the ﬁrst 6 weeks, but it reduced the growth rate of
tumours after the sixth week (Figure 5a). This ﬁnding
supports the tumour-promoting properties of hPTTG1 in
previous studies (Zou et al., 1999). Orthotopic injection of
tumour cells can be used as a spontaneous metastatic
mouse model to determine whether hPTTG1 inﬂuences
the early steps of the invasion-metastasis cascade.
hPTTG1-knockdown MDA-MB-231 cells were strikingly
impaired in their capacity to seed lung metastases
compared with control shGFP-knockdown MDA-MB-
231 cells (Figure 5b). hPTTG1-knockdown MDA-MB-
231 cells formed 80% fewer metastatic nodules than did
controls 10 weeks after implantation.
Knockdown of hPTTG1 consistently decreased GEF-
H1 protein expression in both primary breast tumours
(Supplementary Figures S7aD and E) and metastatic
breast tumours within the lung (Supplementary Figures
S7bC and D). We next asked whether ectopic hPTTG1
is required to induce metastasis. Thus, non-metastatic
MCF-7 cells overexpressing hPTTG1 were also ortho-
topically injected into mice. hPTTG1-overexpressed
MCF-7 cells metastasised to the lungs in signiﬁcant
numbers, whereas control Mock-transfected MCF-7 cells
did not form metastatic nodules (Figure 5c). hPTTG1-
overexpressed MCF-7 cells formed 13-fold more meta-
static nodules than did controls after 16 weeks after
implantation. Overexpression of hPTTG1 also consis-
tently increased GEF-H1 protein expression in both
primary breast tumours (Supplementary Figures S7cD
and E) and metastatic breast tumours within the lung
(Supplementary Figures S6dC and D). However, RhoA
expression was not induced either in MDA-MB-231 or
in MCF-7 tumours (Supplementary Figures S7aC and
F, and S7cC and F). Our results suggest that hPTTG1
speciﬁcally upregulates GEF-H1 expression, thus pro-
moting breast cancer cell invasion and metastasis in vivo.
To determine whether the impact of the hPTTG1/
GEF-H1 axis on metastasis also affects the later steps of
the invasion-metastasis cascade, we injected the control
and hPTTG1-knockdown MDA-MB-231 cells directly
into mouse-tail veins, thereby preventing the early steps
of local invasion and intravasation. After 10 weeks, mice
injected with hPTTG1-knockdown MDA-MB-231 cells
formed 86% fewer metastatic nodules than did control
shGFP-knockdown MDA-MB-231 cells (Figure 5d).
Further, we found that restoration of GEF-H1 expression
led to a recovery of 62% of the metastatic potential in
hPTTG1-knockdown MDA-MB-231 cells (Figure 5d).
These results suggest that the hPTTG1/GEF-H1 axis
regulates the colonisation process of breast cancer cells
into lung and promotes breast cancer metastasis in mice.
hPTTG1 expression is correlated to GEF-H1 expression
in human invasive breast carcinoma
All of the results described above indicated that hPTTG1-
overexpression induced GEF-H1 expression in vitro,a n d
that this signalling axis is critical for breast cancer
invasion and metastasis in mice. Therefore, we investi-
gated the clinical association of hPTTG1 and GEF-H1 in
human breast cancer samples. As hPTTG1 transcription-
ally activates GEF-H1, the prognostic signiﬁcance of
hPTTG1 was determined by assessing its nuclear staining
(Ogbagabriel et al., 2005). Cancer samples were scored on
the basis of the intensity of hPTTG1 nuclear staining and
the percentage of hPTTG1-positive tumour cells; more-
over, the intensity of GEF-H1 nuclear and cytoplasmic
staining in tumour cells were analyzed (described in
Materials and methods). Analyzing human invasive breast
carcinomas (70 cases), hPTTG1 was predominantly
expressed in the nuclei (2þ and 3þ,6 8o u to f7 0 )
(Figure 6Aa and b), whereas GEF-H1 had both a nuclear
and cytoplasmic presence (2þ and 3þ, 65 out of 70)
(Figure 6Ad and e). However, in normal parts of these
specimens, both hPTTG1 and GEF-H1 were expressed
weakly in the cytoplasm (Supplementary Figure S8a).
Indeed, in these 70 specimens, 64 samples showed
abundant expression of both hPTTG1 and GEF-H1,
and their expression levels were signiﬁcantly associated
with each other (P¼0.019) (Figure 6B). Among the
hPTTG1-strong (3þ) group, 32% (8 out of 25) of the
samples showed GEF-H1-strong (3þ) expression, and
64% (16 out of 25) of the samples showed GEF-H1-
moderate (2þ) expression (Supplementary Figure S8b).
In the hPTTG1-moderate (2þ) group, 79% (34 out of
43) of the samples showed GEF-H1-moderate (2þ)
expression (Supplementary Figure S8b).
Taken together, our results establish a molecular link
between hPTTG1 and GEF-H1 in vitro and in vivo. The
results of animal experiments and clinical investigations
emphasise the importance of the hPTTG1/GEF-H1/
RhoA signalling axis in breast cancer metastasis.
Discussion
Our study identiﬁes the role of overexpressed hPTTG1 in
regulating breast cancer metastasis. First, we show that
hPTTG1 directly regulates GEF-H1 gene transcription
and RhoA-GTP activation in breast cancer cells. Second,
we demonstrate that activation of hPTTG1/GEF-H1
signalling is essential for breast cancer cell migration and
invasion, and is required for actin cytoskeleton rearrange-
ments upon RhoA activation. Third, we provide in vivo
evidences that hPTTG1/GEF-H1 signalling is required for
breast cancer metastasis in a mouse model. Finally, the
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OncogeneFigure 5 hPTTG1/GEF-H1 signalling regulates cancer metastasis in a mouse model. (a) Primary tumour growth was measured upon
orthotopic injection of MDA-MB-231 cells with GFP or hPTTG1 knockdown (right). The experiment was terminated after 10 weeks
because of primary tumour burden. Representative tumours are shown in the left panel. n¼6 per group per time point. Each time
point shows the mean±s.e.m. (b) Left panel: Images of murine lungs, 10 weeks after orthotopic implantation of MDA-MB-231 cells
with GFP or hPTTG1 knockdown. H&E stain of lungs from mice bearing the indicated tumours; arrows indicate metastatic foci.
Right panel: Quantitative results of the lung metastasis (n¼6 per group). (c) Left panel: Images of murine lungs, 16 weeks after
orthotopic implantation of mock-transfected or hPTTG1-overexpressed MCF-7 cells. H&E stain of lungs from mice bearing the
indicated tumours; arrows indicate metastatic foci. Right panel: Quantitative results of the lung metastasis (n¼5 per group). (d) Left
panel: Images of murine lungs 10 weeks after tail vein injection of MDA-MB-231 cells with GFP or hPTTG1 knockdown or with
hPTTG1 knockdown plus GEF-H1 overexpression. H&E stain of lungs; arrows indicate metastatic foci. Right panel: Quantitative
results of the lung metastasis (n¼6 per group). Magniﬁcation,  200. Scale bars, 100mm. The numbers of metastatic nodules in H&E
stains were counted microscopically. Data are mean±s.e.m. *Po0.05; ***Po0.0001.
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Oncogeneclinical observations show the positive correlation be-
tween hPTTG1 and GEF-H1 expression in human
invasive breast cancers. This work has revealed that
hPTTG1 activates GEF-H1, as a novel mechanism to
regulate breast cancer metastasis via RhoA signalling.
hPTTG1, a transcription factor, can activate several
genes, such as c-Myc, FGF-2, cyclin D3, p21, sodium-
iodine symporter, prolactin and MMP2 (Pei, 2001; Tong
and Eigler, 2009), and suggested that the transcriptional
activity of hPTTG1 may have important roles in a
variety of cellular processes. Several oncogenic tran-
scription factors can promote malignant progression by
induction of downstream effectors (Clevenger, 2004;
Libermann and Zerbini, 2006). This concept provides a
more plausible explanation as to why hPTTG1 is
expressed at a high level in most malignant breast
cancers. Indeed, our data show that hPTTG1 serves as a
transcription factor to promote breast cancer metastasis
by activating its direct target, GEF-H1. This ﬁnding is
further underscored by clinical observations that tu-
mour tissues of patients with invasive breast carcinoma
express signiﬁcant hPTTG1 nuclear staining, which is
correlated to GEF-H1 expression.
There is strong evidence that both depletion and
overexpression of hPTTG1 can induce apoptosis and
senescence in vitro and in vivo (Chesnokova et al.,2 0 0 8 ;
Chesnokova and Melmed, 2010; Smith et al.,2 0 1 0 ) .T h e s e
studies indicate that the proper amount of hPTTG1 is
important for regulating physiological processes in vitro
and in vivo. Senescence is considered as a ﬁrst-line barrier
to prevent tumour growth and malignant transformation.
Genetic instabilities in cancer cells may cause mutations in
important tumour suppressor genes to help cancer cells
escape senescence and apoptosis. In cancer cells, impaired
regulation of senescence and apoptosis may be important
for hPTTG1 to exert its oncogenic properties. Over-
expression of hPTTG1 can induce DNA damage response
and chromosome instability (Kim et al., 2007), and
overexpression seems to be an essential criterion for
hPTTG1 to enhance its oncogenic potential.
RhoA-GTPase is expressed ubiquitously in different
human tissues (Wennerberg and Der, 2004), and how
RhoA-GTPase is activated pathologically has become
an important issue in cancer biology. GEF-H1 is the
major molecule that regulates the activity of RhoA
physiologically. GEF-H1 activity is regulated by micro-
tubule binding (Krendel et al., 2002), and microtubule
dynamics that speciﬁcally connect cellular RhoA activa-
tion and actin cytoskeleton regulation (Birkenfeld et al.,
2008). Consistent with the fact that GEF-H1 mediates
the RhoA-dependent F-actin stress ﬁbres formation
(Birukova et al., 2006; Chang et al., 2008), our results
show that hPTTG1-induced GEF-H1 expression in-
creased the amount of GTP-bound RhoA, thereby
increasing the assembly of F-actin stress ﬁbres and focal
adhesions in breast cancer cells. GEF-H1 has been
proposed to have a role in regulating the metastatic
capacities of cancer cells because its regulatory effects of
actin cytoskeleton are likely to enhance the migratory
and invasive properties of cancer cells (Birkenfeld et al.,
2008). Such speculation is supported by our observation
that the newly discovered role of hPTTG1/GEF-H1/
RhoA signalling in cytoskeleton regulation, which is one
of the driving forces of breast cancer metastasis.
In this study, we provided a new insight into how
hPTTG1 promotes breast cancer metastasis. Our results
show that overexpressed hPTTG1 directly activates
GEF-H1, which in turn, activates RhoA, a regulator
of actin organisation (Figure 6C). hPTTG1 enhances the
migratory and invasive ability of tumour cells through
RhoA activation. Thus, hPTTG1 is an attractive
therapeutic target for treating metastatic cancers.
Materials and methods
Cell lines and cell culture
MDA-MB-231, MDA-MB-435, MCF-7, BT-483, T47D,
Au565, ZR-75-1 and H184B5F5/M10 cells (from ATCC,
Manassas, VA, USA) were grown in Dulbecco’s modiﬁed Eagle
medium (DMEM) containing 10% fetal bovine serum. HCT116
Figure 6 Positive correlation between hPTTG1 and GEF-H1
expression in invasive breast carcinoma samples. (A) The expres-
sion pattern of hPTTG1 and GEF-H1 in representative tumour
tissues of patients with invasive breast carcinoma. Tissues were
scored as having strong (3þ, a, d), moderate (2þ, b, e), or weak
expression (1þ/0, c, f). The criteria are described in Materials and
methods section. Original magniﬁcation,  400. Scale bars, 50mm.
(B) The expression data of hPTTG1 and GEF-H1 in 70 invasive
breast carcinoma specimens (see Supplementary Figure S7b).
(C) Schematic representation of the role of hPTTG1/GEF-H1/RhoA
signalling in actin cytoskeletal regulation and cancer metastasis.
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Hopkins School of Medicine) were maintained in McCoy’s 5A
medium containing 10% fetal bovine serum. To create
pcDNA3.1-hPTTG1, hPTTG1 was PCR-ampliﬁed from the
cDNA of 293T cells and then subcloned into a pcDNA3.1 vector
(Invitrogen, Carlsbad, CA, USA). hPTTG1-null HCT116 and
MCF-7 cells were transfected with 4mg pcDNA3.1 or pcDNA3.1-
hPTTG1 expression plasmid using Lipofectamine 2000 (Invitro-
g e n )a n dt h e ns e l e c t e dw i t hh y g r o m y c i n( 1 0 0 mg/ml). GEF-H1
expression plasmid was obtained from ORIGENE (Rockville,
MD, USA) (SC323957). MCF-7 cells were transfected with GEF-
H1 expression plasmids and then selected with neomycin (400mg/
ml). To generate control GFP-, hPTTG1- and GEF-H1-knock-
down MDA-MB-231 cells, speciﬁc shRNA reagents were
obtained from the National RNAi Core Facility, Academia
Sinica (Taipei, Taiwan) (GFP-shRNA clone: TRCN0000072178;
hPTTG1-shRNA clone: TRCN0000015103 and TRCN0000015
106). The GEF-H1-shRNA clone (TR314672) was purchased
from ORIGENE. shRNA clones were selected with puromycin
(2mg/ml) for further use. All individual resistant colonies were
isolated and characterised by immunoblot analysis.
Luciferase reporter assays
The regulatory sequence of GEF-H1 (nucleotides  1600 to
þ98, which encompass 1600bp upstream to 98 downstream of
the transcription start site) was PCR-ampliﬁed from human
genomic DNA, and inserted into the pGL3 luciferase vector
(Promega, Madison, WI, USA). MCF-7 cells were transfected
using Lipofectamine 2000, and the luciferase activities were
measured 48h after transfection using the Dual-Luciferase
Reporter System (Promega). Site-speciﬁc mutation of the
GEF-H1 promoter was performed using a QuickChange Site-
Directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA)
following the manufacturer’s instructions.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out in accordance with the
manufacturer’s instructions (Millipore, Billerica, MA, USA).
The chromatin preparation was sheared by sonication, and 1%
of the sheared chromatin was collected as an input control.
The remaining chromatin preparation was incubated with anti-
hPTTG1 (1:100, Invitrogen) or rabbit IgG (1:500, Cell
Signaling, Danvers, MA, USA) for 12h at 41C on a rotating
platform. Real-time PCR was used to enrich promoter-binding
levels, and those data are expressed as fold enrichment (fold
increase over the control IgG). PCR was carried out with primers
a sf o l l o w s :G E F - H 1h P T T G 1B E - 1( b i n d i n gs i t e - 1 ) ,5 0-CCCC
ACCTTACCCTGCTTCTTG-30 and 50-CTCCGCCTCTGCCA
GCTACTTT-30; GEF-H1 hPTTG1 BE-2, 50-GAGCTAGGAG
GAGGGCAGAGT-30 and 50-GCCAGAGGGAGAGGAAAT
CAA-30; and GEF-H1 hPTTG1 BE-3, 50-CCCGCCTTCCCCCA
ACAATAC-30 and 50-CACCCCTACCCACTCGCTCGCA-30.
Immunoblot analysis
The indicated cell lysates were extracted with cell lysis buffer
(iNtRON), and 50mg of protein was subjected to 12% SDS–
polyacrylamide gel electrophoresis analysis. Immunoblot analy-
sis was performed with the antibodies anti-GEF-H1, RhoA
(1:1000, Cell Signaling), b-actin (1:3000, Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA) and hPTTG1 (1:1000, Invitrogen).
RhoA activity assay
To detect activated, GTP-bound RhoA, a RhoA-GTP puriﬁca-
tion kit was used according to the manufacturer’s instructions
(Millipore). Cell lysates were extracted and were used to pull
down activated RhoA-GTP with a glutathione S-transferase-
rhotekin Rho-binding domain, which selectively bound RhoA-
GTP but not RhoA-GDP. After precipitation, samples were
analysed by immunoblot analysis with an anti-RhoA antibody.
Immunoﬂuorescence analysis
C e l l sw e r ec u l t u r e do np o l y - L-lysine-coated slides for 48h, ﬁxed
with 4% paraformaldehyde, and permeabilised with 0.5% Triton-
X 100 in phosphate buffered saline (PBS). Fixed cells were blocked
with 1% bovine serum albumin (BSA) in PBS and incubated with
anti-paxillin (1:200, Cell Signaling) at room temperature for 1h.
After washing three times with PBS, cells were incubated with a
secondary antibody conjugated to ﬂuorescein isothiocyanate
(FITC) and Alexa ﬂour 555-conjugated phalloidin (Invitrogen)
for 1h at room temperature. Nuclei were visualised with 40,60
diamino-2-phenylindole (DAPI). Morphological alterations, actin
ﬁlament formation and paxillin puncta in the cells were observed,
and images were captured with a confocal microscope (LEICA
TCS SP2 AOBS, LEICA, Wetzlar, Germany).
Migration and invasion assays
For the migration assays, 2.5 10
4 cells were seeded in an
uncoated membranes, with 8.0mm pores (Corning, Corning, NY,
USA); for invasion assays, 1 10
5 cells were seeded in a Matrigel-
coated chamber, with 8.0mm pores (BD Bioscience, Franklin
Lakes, NJ, USA). Cells were seeded in a serum-free medium and
migrated toward complete growth media for 12–15h. The
migrating or invading cells in polycarbonate membranes were
stained and counted as previous reported (Chan et al., 2010).
Animal studies
For spontaneous metastasis assay, 2 10
5 tumour cells were
injected into the fourth mammary fat pad of 5- to 8-week-old
SCID mice in 1:1 Matrigel (BD Bioscience) plus PBS. Primary
tumour growth upon orthotopic injection was obtained by weekly
measurements. For the experimental metastasis assay, 1 10
6
tumour cells were injected into the tail vein of 5- to 8-week-old
SCID mice. All dissected lungs were parafﬁn-embedded, sectioned,
stained with haematoxylin and eosin (H&E), and metastatic
nodules counted by microscope (4–5 lobes per lung in a mouse).
An average of metastatic nodules per lung in mice was shown in
Figures 5b–d (right panels). All animals were maintained in the
Laboratory Animal Center at Tzu-Chi University.
Immunohistochemistry (IHC)
Human breast cancer tissue samples (70 patients) were collected
with approval from Tzu-Chi Hospital for immunohistochemistry
analysis. Parafﬁn-embedded tissue sections (3mm) were immunos-
tained following a previously described protocol (Liu et al., 2008),
with the antibodies anti-hPTTG1 (1:100, Invitrogen), anti-GEF-
H1 (1:40, ATLAS Antibody, Stockholm, Sweden) and RhoA
(1:100, Proteintech, Chicago, IL, USA). Nuclei were counter-
stained with haematoxylin. To evaluate the expression levels of
hPTTG1 and GEF-H1, immunostained human breast tissues
were judged by two pathologists using the following criteria.
hPTTG1 was classiﬁed as 3þ (strong hPTTG1 nuclear staining in
45% tumour cells or moderate hPTTG1 nuclear staining in
450% tumour cells), 2þ (moderately positive hPTTG1 nuclear
staining in o50% tumour cells), and 0/1þ ( n oo rw e a kh P T T G 1
nuclear staining), and GEF-H1 was classiﬁed as strong (3þ),
moderate (2þ)o rw e a k( 0 / 1 þ) based on the intensity of both
nuclear and cytoplasmic immunoreactivity. The association of
hPTTG1 expression with GEF-H1 expression in invasive breast
carcinoma was analyzed by Pearson’s correlation test.
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OncogeneStatistical analysis
Data are presented as mean±s.e.m. unless otherwise noted.
Student’s t-test was used for comparisons. Po0.05 was
considered signiﬁcant.
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